98 related articles for article (PubMed ID: 18647973)
1. New treatment strategies provide more options for patients with breast cancer.
Hampton T
JAMA; 2008 Jul; 300(4):381-2. PubMed ID: 18647973
[No Abstract] [Full Text] [Related]
2. Trastuzumab and capecitabine for metastatic breast cancer.
Med Lett Drugs Ther; 1998 Nov; 40(1039):106-8. PubMed ID: 9814369
[No Abstract] [Full Text] [Related]
3. Bevacizumab in breast cancer: fundamental questions remain.
Miles DW
Lancet Oncol; 2013 Feb; 14(2):99-101. PubMed ID: 23369679
[No Abstract] [Full Text] [Related]
4. [Breast Cancer Conference. Trastuzumab and capecitabine in the treatment of advanced breast cancer. Milano, 6-7 June 2002].
Longo F; Mansueto G
Tumori; 2002; 88(5):A1-10. PubMed ID: 12489530
[No Abstract] [Full Text] [Related]
5. Bone targeted therapy in breast cancer: present and future.
Huober J; Thürlimann B
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S7-10. PubMed ID: 20427030
[No Abstract] [Full Text] [Related]
6. Drug update: emerging therapies for breast cancer.
Valgus JM
Cancer Pract; 1999; 7(2):100-3. PubMed ID: 10352069
[No Abstract] [Full Text] [Related]
7. Evolving treatment of advanced colon cancer.
Segal NH; Saltz LB
Annu Rev Med; 2009; 60():207-19. PubMed ID: 19630571
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
9. [Effects of zoledronic acid in the treatment of breast cancer].
Chen J; Liu ZY; Zhao LJ
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):318-9. PubMed ID: 21575510
[No Abstract] [Full Text] [Related]
10. State-of-the-art chemotherapy for advanced breast cancer.
Piccart MJ; Awada A
Semin Oncol; 2000 Oct; 27(5 Suppl 9):3-12. PubMed ID: 11049051
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib in metastatic breast cancer.
Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in adjuvant treatment of early breast cancer.
; Harbeck N; von Minckwitz G; Thürlimann B
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S1. PubMed ID: 20427026
[No Abstract] [Full Text] [Related]
13. Denosumab an option for patients with bone metastasis from breast cancer.
Barton MK
CA Cancer J Clin; 2011; 61(3):135-6. PubMed ID: 21532096
[No Abstract] [Full Text] [Related]
14. Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Miles D; Zielinski C; Martin M; Vrdoljak E; Robert N
Eur J Cancer; 2012 Mar; 48(4):482-91. PubMed ID: 22257791
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Miller KD; Chap LI; Holmes FA; Cobleigh MA; Marcom PK; Fehrenbacher L; Dickler M; Overmoyer BA; Reimann JD; Sing AP; Langmuir V; Rugo HS
J Clin Oncol; 2005 Feb; 23(4):792-9. PubMed ID: 15681523
[TBL] [Abstract][Full Text] [Related]
16. Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.
Diel I; Aebi S
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S11-5. PubMed ID: 20427027
[No Abstract] [Full Text] [Related]
17. Length of chemotherapy and use of bevacizumab for breast cancer.
Brufsky A
Lancet Oncol; 2014 Nov; 15(12):1285-7. PubMed ID: 25439683
[No Abstract] [Full Text] [Related]
18. The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ..
Gnant M; Eidtmann H
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S2-6. PubMed ID: 20427029
[No Abstract] [Full Text] [Related]
19. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
[TBL] [Abstract][Full Text] [Related]
20. Moving forward with capecitabine: a glimpse of the future.
Biganzoli L; Martin M; Twelves C
Oncologist; 2002; 7 Suppl 6():29-35. PubMed ID: 12454317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
